Cargando…

A global profile of gene promoter methylation in treatment-naïve urothelial cancer

The epigenetic alteration of aberrant hypermethylation in the promoter CpG island of a gene is associated with repression of transcription. In neoplastic cells, aberrant hypermethylation is well described as a mechanism of allele inactivation of particular genes with a tumor suppressor function. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibragimova, Ilsiya, Dulaimi, Essel, Slifker, Michael J, Chen, David DY, Uzzo, Robert G, Cairns, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063835/
https://www.ncbi.nlm.nih.gov/pubmed/24521710
http://dx.doi.org/10.4161/epi.28078
_version_ 1782321866971545600
author Ibragimova, Ilsiya
Dulaimi, Essel
Slifker, Michael J
Chen, David DY
Uzzo, Robert G
Cairns, Paul
author_facet Ibragimova, Ilsiya
Dulaimi, Essel
Slifker, Michael J
Chen, David DY
Uzzo, Robert G
Cairns, Paul
author_sort Ibragimova, Ilsiya
collection PubMed
description The epigenetic alteration of aberrant hypermethylation in the promoter CpG island of a gene is associated with repression of transcription. In neoplastic cells, aberrant hypermethylation is well described as a mechanism of allele inactivation of particular genes with a tumor suppressor function. To investigate the role of aberrant hypermethylation in the biology and progression of urothelial cancer, we examined 101 urothelial (transitional cell) carcinomas (UC), broadly representative of the disease at presentation, with no prior immunotherapy, chemotherapy or radiotherapy, by Infinium HM27 containing 14,495 genes. The genome-wide signature of aberrant promoter hypermethylation in UC consisted of 729 genes significant by a Wilcoxon test, hypermethylated in a CpG island within 1 kb of the transcriptional start site and unmethylated in normal urothelium from aged individuals. We examined differences in gene methylation between the two main groups of UC: the 75% that are superficial, which often recur but rarely progress, and the 25% with muscle invasion and poor prognosis. We further examined pairwise comparisons of the pathologic subgroups of high or low grade, invasive or non-invasive (pTa), and high grade superficial or low grade superficial UC. Pathways analysis indicated over-representation of genes involved in cell adhesion or metabolism in muscle-invasive UC. Notably, the TET2 epigenetic regulator was one of only two genes more frequently methylated in superficial tumors and the sole gene in low grade UC. Other chromatin remodeling genes, MLL3 and ACTL6B, also showed aberrant hypermethylation. The Infinium methylation value for representative genes was verified by pyrosequencing. An available mRNA expression data set indicated many of the hypermethylated genes of interest to be downregulated in UC. Unsupervised clustering of the most differentially methylated genes distinguished muscle invasive from superficial UC. After filtering, cluster analysis showed a CpG Island Methylator Phenotype (CIMP)-like pattern of widespread methylation in 11 (11%) tumors. Nine of these 11 tumors had hypermethylation of TET2. Our analysis provides a basis for further studies of hypermethylation in the development and progression of UC.
format Online
Article
Text
id pubmed-4063835
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40638352015-05-01 A global profile of gene promoter methylation in treatment-naïve urothelial cancer Ibragimova, Ilsiya Dulaimi, Essel Slifker, Michael J Chen, David DY Uzzo, Robert G Cairns, Paul Epigenetics Research Paper The epigenetic alteration of aberrant hypermethylation in the promoter CpG island of a gene is associated with repression of transcription. In neoplastic cells, aberrant hypermethylation is well described as a mechanism of allele inactivation of particular genes with a tumor suppressor function. To investigate the role of aberrant hypermethylation in the biology and progression of urothelial cancer, we examined 101 urothelial (transitional cell) carcinomas (UC), broadly representative of the disease at presentation, with no prior immunotherapy, chemotherapy or radiotherapy, by Infinium HM27 containing 14,495 genes. The genome-wide signature of aberrant promoter hypermethylation in UC consisted of 729 genes significant by a Wilcoxon test, hypermethylated in a CpG island within 1 kb of the transcriptional start site and unmethylated in normal urothelium from aged individuals. We examined differences in gene methylation between the two main groups of UC: the 75% that are superficial, which often recur but rarely progress, and the 25% with muscle invasion and poor prognosis. We further examined pairwise comparisons of the pathologic subgroups of high or low grade, invasive or non-invasive (pTa), and high grade superficial or low grade superficial UC. Pathways analysis indicated over-representation of genes involved in cell adhesion or metabolism in muscle-invasive UC. Notably, the TET2 epigenetic regulator was one of only two genes more frequently methylated in superficial tumors and the sole gene in low grade UC. Other chromatin remodeling genes, MLL3 and ACTL6B, also showed aberrant hypermethylation. The Infinium methylation value for representative genes was verified by pyrosequencing. An available mRNA expression data set indicated many of the hypermethylated genes of interest to be downregulated in UC. Unsupervised clustering of the most differentially methylated genes distinguished muscle invasive from superficial UC. After filtering, cluster analysis showed a CpG Island Methylator Phenotype (CIMP)-like pattern of widespread methylation in 11 (11%) tumors. Nine of these 11 tumors had hypermethylation of TET2. Our analysis provides a basis for further studies of hypermethylation in the development and progression of UC. Landes Bioscience 2014-05-01 2014-02-12 /pmc/articles/PMC4063835/ /pubmed/24521710 http://dx.doi.org/10.4161/epi.28078 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Research Paper
Ibragimova, Ilsiya
Dulaimi, Essel
Slifker, Michael J
Chen, David DY
Uzzo, Robert G
Cairns, Paul
A global profile of gene promoter methylation in treatment-naïve urothelial cancer
title A global profile of gene promoter methylation in treatment-naïve urothelial cancer
title_full A global profile of gene promoter methylation in treatment-naïve urothelial cancer
title_fullStr A global profile of gene promoter methylation in treatment-naïve urothelial cancer
title_full_unstemmed A global profile of gene promoter methylation in treatment-naïve urothelial cancer
title_short A global profile of gene promoter methylation in treatment-naïve urothelial cancer
title_sort global profile of gene promoter methylation in treatment-naïve urothelial cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063835/
https://www.ncbi.nlm.nih.gov/pubmed/24521710
http://dx.doi.org/10.4161/epi.28078
work_keys_str_mv AT ibragimovailsiya aglobalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT dulaimiessel aglobalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT slifkermichaelj aglobalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT chendaviddy aglobalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT uzzorobertg aglobalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT cairnspaul aglobalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT ibragimovailsiya globalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT dulaimiessel globalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT slifkermichaelj globalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT chendaviddy globalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT uzzorobertg globalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer
AT cairnspaul globalprofileofgenepromotermethylationintreatmentnaiveurothelialcancer